Skip to main content

Midol Maximum Strength Cramp Formula and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with Midol Maximum Strength Cramp Formula (ibuprofen).

Moderate

Ibuprofen Alcohol (Ethanol)

Moderate Drug Interaction

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References (1)
  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn

Switch to consumer interaction data

Major

Ibuprofen High Blood Pressure (Hypertension)

Major Potential Hazard, Moderate plausibility

NSAIDs - fluid retention

Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations. NSAIDs (including topicals) can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. NSAIDs should be used with caution in patients with preexisting fluid retention, hypertension, or history of heart failure. NSAIDs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure; if an NSAID is used in such patients, they should be monitored for signs of worsening heart failure. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.

References (20)
  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
  2. (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
  3. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  4. (2002) "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories
  5. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  6. (2006) "Product Information. Anaprox (naproxen)." Roche Laboratories
  7. (2001) "Product Information. Clinoril (sulindac)." Merck & Co., Inc
  8. (2001) "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical
  9. (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
  10. (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
  11. (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
  12. (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
  13. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  14. (2001) "Product Information. Daypro (oxaprozin)." Searle
  15. (2001) "Product Information. Celebrex (celecoxib)." Searle
  16. (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
  17. (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
  18. (2016) "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)
  19. (2022) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals Group, SUPPL-52
  20. (2025) "Product Information. Symbravo (meloxicam-rizatriptan)." Axsome Therapeutics, Inc.

Switch to consumer interaction data

Midol Maximum Strength Cramp Formula drug interactions

There are 414 drug interactions with Midol Maximum Strength Cramp Formula (ibuprofen).

Midol Maximum Strength Cramp Formula disease interactions

There are 11 disease interactions with Midol Maximum Strength Cramp Formula (ibuprofen) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer